Table 1.
Patient characteristics, according to mutational signature status
| Characteristic | All patients (n = 76) | SBS4 (n = 25) | SBS2/13 (n = 11) | SBS29 (n = 5) | Other (n = 37) |
|---|---|---|---|---|---|
| Age at enrollment—years | |||||
| Mean ± SD | 63.7 ± 9.8 | 63.7 ± 9.2 | 67.9 ± 8.4 | 69.8 ± 9.6 | 65.1 ± 10.6 |
| Median (range) | 67 (34–87) | 62 (45–80) | 68 (52–81) | 75 (58–79) | 68 (34–87) |
| Sex—no. (%) | |||||
| Female | 41 (54) | 14 (56) | 6 (55) | 3 (60) | 14 (38) |
| Male | 35 (46) | 11 (44) | 5 (45) | 2 (40) | 23 (62) |
| Histological diagnosis—no. (%) | |||||
| Adenocarcinoma | 43 (57) | 17 (68) | 7 (64) | 3 (60) | 18 (49) |
| Squamous-cell carcinoma | 11 (14) | 3 (12) | 1 (9) | 1 (20) | 6 (16) |
| Large cell neuroendrocrine carcinoma | 4 (5) | 1 (4) | 0 (0) | 0 (0) | 3 (8) |
| Other | 18 (24) | 4 (16) | 3 (27) | 1 (20) | 10 (27) |
| Clinical stage—no. (%) | |||||
| I | 11 (14) | 8 (32) | 3 (27) | 1 (20) | 0 (0) |
| II | 9 (12) | 4 (16) | 2 (18) | 0 (0) | 3 (8) |
| III | 20 (27) | 5 (20) | 1 (9) | 3 (60) | 12 (32) |
| IV | 36 (47) | 8 (32) | 5 (46) | 1 (20) | 22 (60) |
| Smoking status—no. (%) | |||||
| Active or former | 72 (95) | 24 (96) | 11 (100) | 5 (100) | 34 (92) |
| Never | 3 (4) | 1 (4) | 0 (0) | 0 (0) | 2 (5) |
| Unknown | 1 (1) | 0 (4) | 0 (0) | 0 (0) | 1 (3) |
| PD-L1 status – no. (%) | |||||
| < 1% | 22 (29) | 5 (20) | 4 (36) | 1 (20) | 12 (32) |
| 1–50% | 13 (17) | 5 (20) | 0 (0) | 1 (20) | 8 (22) |
| > 50% | 25 (33) | 10 (40) | 4 (36) | 2 (40) | 9 (24) |
| Unknown | 16 (21) | 5 (20) | 3 (28) | 1 (20) | 8 (22) |